The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 08, 2009
Filed:
May. 18, 2006
Shunichiro Hachiya, Tokyo, JP;
Makoto Oku, Chuo-ku, JP;
Hana Mukai, Chuo-ku, JP;
Takashi Shin, Chuo-ku, JP;
Keisuke Matsuura, Chuo-ku, JP;
Ryushi Seo, Chuo-ku, JP;
Takashi Kamikubo, Chuo-ku, JP;
Yoh Terada, Chuo-ku, JP;
Masanao Sanagi, Chuo-ku, JP;
Kousei Yoshihara, Chuo-ku, JP;
Taisuke Takahashi, Chuo-ku, JP;
Shunichiro Hachiya, Tokyo, JP;
Makoto Oku, Chuo-ku, JP;
Hana Mukai, Chuo-ku, JP;
Takashi Shin, Chuo-ku, JP;
Keisuke Matsuura, Chuo-ku, JP;
Ryushi Seo, Chuo-ku, JP;
Takashi Kamikubo, Chuo-ku, JP;
Yoh Terada, Chuo-ku, JP;
Masanao Sanagi, Chuo-ku, JP;
Kousei Yoshihara, Chuo-ku, JP;
Taisuke Takahashi, Chuo-ku, JP;
Astellas Pharma Inc., Tokyo, JP;
Abstract
[Problem] To provide a compound which may be used in treating diseases in which a calcium sensing receptor (CaSR) is concerned, particularly hyperparathyroidism. [Means for Resolution] It was found that novel pyrrolidine derivatives which are characterized by the possession of aminomethyl group substituted with arylalkyl group or the like, or salts thereof, have excellent CaSR agonistic regulatory activity and also have excellent selectivity with CYP2D6 inhibitory activity having a possibility of causing drug interaction. Based on the above, these novel pyrrolidine derivatives are useful as therapeutic agents for treating diseases in which CaSR is concerned (hyperparathyroidism, renal osteodystrophy, hypercalcemia and the like).